To the full analysis
Buyback calculator for Xeris Biopharma Holdings
Xeris Biopharma Holdings stock: dividend
XERSXeris Biopharma Holdings does not currently pay a dividend. From fiscal 2023 to 2025, Xeris Biopharma Holdings bought back its own shares for $15.62M.
Whether Xeris Biopharma Holdings, Inc. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | $27.93M | $10.88M | 160.43M |
| 2024 | −$37.85M | $3.73M | 146.77M |
| 2023 | −$49.29M | $1.01M | 137.67M |
| 2022 | −$103.42M | $468K | 135.63M |
| 2021 | −$96.62M | $534K | 79.03M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.